{"id":"onabotulinumtoxina-44-u","safety":{"commonSideEffects":[{"rate":"null","effect":"Eyelid ptosis"},{"rate":"null","effect":"Diplopia"},{"rate":"null","effect":"Headache"},{"rate":"null","effect":"Facial asymmetry"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"It does this by blocking the release of acetylcholine, a neurotransmitter that signals muscle contraction. This results in a temporary reduction in muscle activity, which can help alleviate symptoms of conditions such as blepharospasm, strabismus, and cervical dystonia.","oneSentence":"onabotulinumtoxinA 44 U works by temporarily paralyzing muscles to treat various conditions.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:24:19.175Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Blepharospasm"},{"name":"Strabismus"},{"name":"Cervical dystonia"},{"name":"Hemifacial spasm"},{"name":"Spasticity"},{"name":"Hyperhidrosis"},{"name":"Aesthetic uses (e.g. facial wrinkles)"}]},"trialDetails":[{"nctId":"NCT01189760","phase":"PHASE3","title":"Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Crow's Feet Lines and Frown Lines","status":"COMPLETED","sponsor":"Allergan","startDate":"2010-09-01","conditions":"Facial Rhytides, Crow's Feet Lines, Glabellar Lines","enrollment":917},{"nctId":"NCT01797094","phase":"PHASE3","title":"BOTOX® in the Treatment of Upper Facial Lines in Japan","status":"COMPLETED","sponsor":"Allergan","startDate":"2013-02","conditions":"Upper Facial Rhytides, Crow's Feet Lines, Glabellar Lines","enrollment":101},{"nctId":"NCT01224015","phase":"PHASE3","title":"Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Crow's Feet Lines and Frown Lines","status":"COMPLETED","sponsor":"Allergan","startDate":"2011-05","conditions":"Facial Rhytides, Crow's Feet Lines, Glabellar Lines","enrollment":684}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":3,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["BOTOX®","BOTOX® Cosmetic","onabotulinumtoxinA"],"phase":"phase_3","status":"active","brandName":"onabotulinumtoxinA 44 U","genericName":"onabotulinumtoxinA 44 U","companyName":"Allergan","companyId":"allergan","modality":"Biologic","firstApprovalDate":"","aiSummary":"OnabotulinumtoxinA 44 U is used to treat facial rhytides, including crow's feet lines and frown lines, as well as glabellar lines and upper facial rhytides. It is administered via injection, with its exact mechanism of action involving the inhibition of acetylcholine release, as indicated by its classification in ChEMBL.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}